| 1. Pardoll, DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer .2012;12(4) 252–264. 2. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications[J].Cancer J.2014;20(4):265-71. 3. Jadus MR, Natividad J, Mai A,et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention[J].Clin Dev Immunol. 2012;2012: 160724. 4. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody[J]. Blood.2010;116(13): 2286–2294. 5. Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities[J]. Crit Rev Oncol Hematol.2014;89(1):140-65. 6. Baral A, Ye HX, Jiang PC, et al. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patient[J].Oncol Lett.2014;8(3):1195-1201. 7. Lu B, Chen L, Zhu Y, et al. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract[J].Immunol Res. 2011;50(2-3):269-75. 8. Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol.2012;2012: 656340. 9. Chen L, Deng H, Lu M, et al.B7-H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer[J]. Int J Clin Exp Pathol.2014;7(9):6015-23. 10. Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer[J].Cell Mol Immunol. 2010;7(5):389-95. 11. McGee HS, Yaqita H, Shao Z, et al. Programmed Death-1 antibody blocks therapeutic effect of T-regulatory cells in cockroach antigen-induced allergic asthma[J].Am J Respir Cell Mol Biol.2010;43(4):432-42. 12. Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4,PD-1/PD-L1,or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment[J]. J Immunother Cancer. 2014;2:3. 13.McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy[J]. Cancer Med. 2013;2(5):662-73. 14. Jaikumar Duraiswamy, Karen M, Kaluza, et al. Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors[J]. Cancer Res.2013;73(12):3591-3603. 15. West EE, Jin HT, Rasheed AU, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells[J]. J Clin Invest.2013;123(6):2604-15. 16.Mkrtichyan M, Chong N, Abu Eid R, et al. Anti-PD-1 antibody significantly increase therapeutic efficacy of Listeria monocytogenes(Lm)-LLO immunotherapy[J].J Immunother Cancer.2013;1:15. 17.Kono K. Current status of cancer immunotherpy[J]. J Stem Cels Regen Med.2014;10(1):8-13. 18. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy[J].J Immunother. 2010;33(3): 225–235. 19. Wang S, Wang Y, Liu J, et al. Sliencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro[J].Onco Targets Ther. 2014;7:1389-96. 20. Maekawa N, Konnai S, Ikebuchi R, et al.Expression of PD-L1 on canine tumor cells and enhancement of INF-γproduction from tumor-infiltrating cells by PD-L1 blockade[J]. PLoS One.2014;9(6):e98415. 21. Rosenblatt J, Glotabecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine[J].J Immunother. 2011;34(5):409-18. 22. Han L, Liu F, Li R, et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma[J]. Oncol Lett.2014;8(4):1461-1469. 23. Sznol M. Blockade of B7-H1/PD1 pathway as a basis for combination anticancer therapy[J]. Cancer J. 2014;20(4):290-5. 24. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med. 2012;366(26):2455-65. 25. Lu J1, Lee-Gabel L2, Nadeau MC2, et al. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy[J]. J Oncol Pharm Pract. 2014 , 9. pii: 1078155214538087. 26. Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-lin[J]e. Front Oncol. 2014 Jun 27,4,157. 27. Langer CJ. Emerging Immunotherapies in the Treatment of Non-Small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors[J].. Am J Clin Oncol. 2014, 28. [Epub ahead of print] 28. Shih K, Arhenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies[J]. Drugs. 2014;74(17):1993-2013. 29. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med. 2013;369(2):122-33. 30. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med. 2010;363(8):711-23. 31. Lina TT, Alzahrani S, Gonzalez J, et al. Immune evasion strategies used by Helicobacter pylori[J].World J Gastroenterol. 2014;20(36):12753-12766. 32. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med.2012;366(26):2443-54. 33. Herbst RS, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors[J]. J Clin Oncol.2013; 31:3000. 34. Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. Front. Pharmacol[J]. 2012;3:8. 35. Evers R, Dallas S, Dickmann LJ, et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper[J]. Drug Metab Dispos. 2013;41(9):1598-609. 36. Lee JI, Zhang L, Men A.Y, et al.CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications[J]. Clin Pharmacokinet. 2010;49(5):295-310. |
